

[ABSTRACT]

The present invention provides a conjugate which has stability improved more than conventional conjugates without impairing the efficacy. The conjugate of the present invention
5 is a conjugate of an anti-HER2 antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond.

10

[No suitable figure]